Unlock instant, AI-driven research and patent intelligence for your innovation.

Processing method for raw drug particles of non-uniform particle size

A technology of raw materials and granules, which is applied in the direction of pharmaceutical formulas, medical preparations containing active ingredients, and medical preparations containing active ingredients. Content uniformity and other issues, to achieve the effect of excellent drug content uniformity, easy amplification, and improved fluidity

Active Publication Date: 2021-02-09
NIPPON ZOKI PHARM CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in scale-up, for example, in batch fluidized bed granulation, there is the following problem: the larger the equipment, the higher the amount of feed per unit area (kg / m 2 : charging density) becomes larger and the charging thickness increases, so the thickness density of the particles applied to the granulation becomes larger
These bulk drug particles with a lot of static electricity are extremely difficult to flow back to the spray area even if they are shaken off by shaking off, which is likely to become a factor that damages the uniformity of content
In addition, even when stirring and mixing with a batch-type stirring granulator (vertical granulator: manufactured by Powrex, etc.), although the whole is uniform, there may be small lumps formed by secondary aggregation locally
The small pieces formed by the secondary aggregation are extremely difficult to disperse, so granulation is carried out in the state of small pieces formed by the secondary aggregation, and as a result, there may be problems in content uniformity such as stains and spots.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Processing method for raw drug particles of non-uniform particle size
  • Processing method for raw drug particles of non-uniform particle size
  • Processing method for raw drug particles of non-uniform particle size

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] 200.0 g and Add 35.0 g of crystalline cellulose (KG-1000), 2.5 g of surfactant (solubilizer) powder, and D-mannitol (trade name: Mannit P Mitsubishi Shoji Foodtech Co. Ltd.) 25.0 g, crushing, sizing, and uniform dispersion to obtain 264.0 g of powder for direct compression. This powder was compressed with a tablet press machine (VEL5 type, tablet pressure 14 kN) manufactured by Kikusui Seisakusho to obtain a tablet with a tablet hardness of 119N. In addition, the 15-minute dissolution rate of this tablet was 89%.

[0079] [Ingredient (compounding amount)] [compounding rate (weight%)]

[0080] Pregabalin (200.0g) 74.75%

[0081] (Compared to 100% of pregabalin, 31% of particles larger than 500μm, 14.5% of particles smaller than 60μm)

[0082] Carplex (1.5g) 0.56%

[0083] Broken Whole Grain 1 (Supermasscolloider)

[0084] (Compared to 100% of powder after crushing and sizing 1, 12.5% ​​of particles over 180μm, 1.5% of particles under 60μm)

[0085]

[0086] (Comp...

Embodiment 2

[0088] Use a crushing granulator (Supermasscolloider) to crush and granulate pregabalin powder 300.0g and Carplex 1.6g, which contain 31% of particles above 500 μm and 14.5% of particles below 60 μm, and uniformly disperse them, and add a disintegrant ( L-HPC) 5.0 g, lactose hydrate 22.0 g and polyethylene glycol powder 5.5 g were crushed, sized and uniformly dispersed to obtain 334.1 g of powder. This powder was compressed with a tablet press machine (VEL5 type, tablet pressure 14 kN) manufactured by Kikusui Seisakusho to obtain a tablet with a tablet hardness of 117N. In addition, the 15-minute dissolution rate of this tablet was 89%.

[0089] [Ingredient (compounding amount)] [compounding rate (weight%)]

[0090] Pregabalin (300.0g) 89.8%

[0091] (Compared to 100% of pregabalin, 31% of particles larger than 500μm, 14.5% of particles smaller than 60μm)

[0092] Carplex (1.6g) 0.5%

[0093] Broken Whole Grain 1 (Supermasscolloider)

[0094] (Compared to 100% of powder a...

Embodiment 3

[0099] Add 1.5 g of Carplex and 15.0 g of a disintegrant (L-HPC) to 200.0 g of celecoxib powder containing 32.1% of particles of 500 μm or more and 18.5% of particles of 60 μm or less, and use a crushing and sizing machine ( Supermasscolloider) was crushed, granulated, and uniformly dispersed, and 48.0 g of lactose hydrate, 5.5 g of polyethylene glycol 4000 powder, 9.0 g of HPC-SSL, and 2.0 g of lubricant were added to the obtained powder, and the powder was crushed, sized, and uniformly dispersed. 281.0 g of a powder for direct compression was obtained. This powder was tabletted with a tablet press machine (VEL5 type, tablet pressure 14 kN) manufactured by Kikusui Seisakusho to obtain a tablet with a tablet hardness of 121N. In addition, the 15-minute dissolution rate of this tablet was 91%.

[0100] [Ingredient (compounding amount)] [compounding rate (weight%)]

[0101] Celecoxib (200.0g) 71.2%

[0102] (With respect to celecoxib 100%, 32.1% of particles larger than 500μm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
sizeaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pre-processing method for the purpose of formulating a raw drug of unsorted particle sizes into a drug through a production method having excellent production performance. According to the pre-processing method of the present invention, a raw drug having a specific particle size distribution and an additive including at least a dispersant are mixed, cracked and sized, thereby dispersing and adhering the additive to the surface of the raw drug particles to yield a powder having a specific particle size distribution. This allows a pharmaceutical formulation tobe produced via a direct tableting method, continuous wet granulation system, or the like, with excellent production performance, production efficiency, and production cost. Thus, the invention is extremely useful.

Description

technical field [0001] The present invention relates to a pretreatment method such as a tableting step or a granulation step in the manufacture of pharmaceutical preparations using raw materials with inconsistent powder physical properties (particle diameter, particle shape, density, etc.). Background technique [0002] In the manufacture of pharmaceutical preparations, as a method of manufacturing tablets in solid preparations, for example, there is a dry direct tableting method (also called "dry tableting method") in which a mixture of a drug substance and additives is compressed without preparing granules. Type direct compression method", or simply referred to as "direct compression method".); through dry granulation method (roller compactor method, roll granulator method) or wet granulation Method (stirring granulation method, extrusion granulation method, spray granulation method, fluidized bed granulation method) and other methods to prepare granules and then compress ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K9/20A61K31/167A61K31/192A61K31/197A61K31/63A61K47/02A61K47/04A61K47/10A61K47/26A61K47/32A61K47/34A61K47/36A61K47/38
CPCA61K31/167A61K31/192A61K31/197A61K31/635A61K9/1611A61K9/1652A61K9/16A61K9/20A61K45/06A61K47/02A61K47/38
Inventor 坂本浩驹居邦男福田清难波健介下赤佳绪里
Owner NIPPON ZOKI PHARM CO LTD